Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.

[1]  F. Durand,et al.  Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients , 2003, Journal of Clinical Microbiology.

[2]  M. Kitzis,et al.  Vancomycin-resistant Staphylococcus aureus: no apocalypse now. , 2003, Clinical Microbiology and Infection.

[3]  Susan K. Johnson,et al.  Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Buiting,et al.  High Percentage of Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides in The Netherlands , 2003, Journal of Clinical Microbiology.

[5]  Fred C Tenover,et al.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. , 2003, The New England journal of medicine.

[6]  A. Tomasz,et al.  Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.

[7]  M. Moore,et al.  Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.

[8]  S. Fridkin,et al.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Manuel,et al.  Detection of teicoplanin resistance in UK EMRSA-17 strains. , 2002, The Journal of antimicrobial chemotherapy.

[10]  M. Struelens,et al.  Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. , 2002, The Journal of antimicrobial chemotherapy.

[11]  R. Auckenthaler,et al.  Molecular epidemiology of predominant clones and sporadic strains of methicillin resistant Staphylococcus aureus in Switzerland and comparison with European epidemic clones. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  C. Kibbler,et al.  Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. , 2002, The Journal of antimicrobial chemotherapy.

[13]  R. Paton,et al.  Glycopeptide resistance in an epidemic strain of methicillin-resistant Staphylococcus aureus. , 2001, The Journal of antimicrobial chemotherapy.

[14]  S. McAllister,et al.  Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. , 2001, Emerging infectious diseases.

[15]  K. Hiramatsu.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. , 2001, The Lancet. Infectious diseases.

[16]  H. Labischinski,et al.  Emergence, Mechanism, and Clinical Implications of Reduced Glycopeptide Susceptibility in Staphylococcus aureus , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[17]  P. Francioli,et al.  Epidemiological Validation of Pulsed-Field Gel Electrophoresis Patterns for Methicillin-ResistantStaphylococcus aureus , 2001, Journal of Clinical Microbiology.

[18]  A. MacGowan,et al.  Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides , 2001, Journal of Clinical Microbiology.

[19]  A. MacGowan,et al.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.

[20]  F. Tenover,et al.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. , 2001, Emerging infectious diseases.

[21]  J. Mainardi,et al.  Outbreak of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Glycopeptides in a Parisian Hospital , 2000, Journal of Clinical Microbiology.

[22]  M. Struelens,et al.  Clonal dissemination of epidemic methicillin-resistant Staphylococcus aureus in Belgium and neighboring countries. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  R. Jayaswal,et al.  Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds , 2000, Antimicrobial Agents and Chemotherapy.

[24]  R. Gaynes,et al.  Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals , 1999, Journal of Clinical Microbiology.

[25]  J. Ariza,et al.  Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin , 1999, The Lancet.

[26]  A. Vatopoulos,et al.  Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. , 1999, The Journal of antimicrobial chemotherapy.

[27]  B. Robinson-Dunn,et al.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. , 1999, The New England journal of medicine.

[28]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[29]  C. Martín,et al.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital , 1998, The Lancet.

[30]  F. Tenover,et al.  Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides , 1998, Journal of Clinical Microbiology.

[31]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[32]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[33]  M. Struelens.  Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems. , 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[35]  R. Howe,et al.  The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. , 2002, Annual review of microbiology.

[36]  J. Liñares,et al.  The VISA/GISA problem: therapeutic implications. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.